Mirum Pharmaceuticals, Inc. (MIRM) financial statements and ratios from SEC XBRL: revenue $0.6B (TTM), net margin -4.5%, revenue growth 54.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $521.31M |
| Revenue (TTM) | $0.6B |
| Net Margin | -4.5% |
| Operating Margin (TTM) | -139.8% |
| Revenue Growth (YoY) | 54.7% |
| EPS Growth (YoY) | -74.6% |
| FCF Growth (YoY) | 488.0% |
| Price / Book | 24.21 |
| Price / Sales | 11.03 |
| FCF Yield | -2.9% |
| Altman Z-Score | 6.51 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
MIRM overview · MIRM earnings · MIRM KPIs · MIRM documents · MIRM ownership · MIRM peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.